Eric Sagonowsky

Editor

Eric Sagonowsky is an editor with FiercePharma and FierceVaccines. He joined the Fierce staff in November 2014 and covers topics such as drug pricing, biosimilars and product liability litigation.

Stories by Eric Sagonowsky

Novo CEO sees its next decade fueled by diabetes know-how, deals

by Eric Sagonowsky

Wednesday, November 20, 2019

Novo faces intense competition in diabetes, but the company can succeed with strong offerings, CEO Lars Fruergaard Jørgensen said at an event.

FDA nominee Hahn promises to put science above politics

by Eric Sagonowsky

Wednesday, November 20, 2019

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

Q3 growth charts: AZ, Merck lead as Teva and Pfizer lag

by Eric Sagonowsky

Tuesday, November 19, 2019

A look at third-quarter numbers shows many top players are rolling right along—though some Big Pharmas weren't so lucky.

Amgen, struggling with copycat rivals, plots 172 more job cuts

by Eric Sagonowsky

Tuesday, November 19, 2019

Last week, Amgen said it's laying off neuroscience R&D staff on the East Coast. Now, it's planning to shed jobs in operations, sales and more.

Pfizer wins FDA nod for Humira biosim, plans 2023 launch

by Eric Sagonowsky

Monday, November 18, 2019

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

Oklahoma judge chops $107M from J&J's opioid verdict

by Eric Sagonowsky

Monday, November 18, 2019

Judge Thad Balkman in Oklahoma reduced J&J's opioid verdict to $465 million to cover one year of crisis abatement, WSJ reports.

Trump says international pricing proposal not 'satisfactory'

by Eric Sagonowsky

Monday, November 18, 2019

The Trump administration is already pushing to lower Part B drug costs to levels similar to other countries. Now, it's planning to go even further.

GSK's Shingrix supply will leap up, CEO says—in 2024, that is

by Eric Sagonowsky

Friday, November 15, 2019

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Intercept amps up sales force ahead of potential NASH rollout

by Eric Sagonowsky

Thursday, November 14, 2019

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.

Chugai claims Alexion used its patented tech to build Ultomiris

by Eric Sagonowsky

Wednesday, November 13, 2019

Alexion is working to switch patients from Soliris to its newer Ultomiris.